Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial.
Aponte Becerra L, Galindo Mendez B, Khan F, Lioutas V, Novak P, Mantzoros C, Ngo L, Novak V. Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial. Archives Of Diabetes & Obesity 2022, 4: 403-415. PMID: 35903156, PMCID: PMC9328174.Peer-Reviewed Original ResearchContinuous glucose monitoringIntranasal insulinGlycemic variabilitySystemic insulinAdverse eventsPlacebo treatmentHypoglycemic episodesWeight gainDouble-blinded placeboSerious adverse eventsDouble-blinded trialType 2 diabetesSubcutaneous insulinDiabetes burdenPlasma glucoseCapillary glucoseInsulin sensitivitySub studyLong-term effectsSafety outcomesTrial participantsGlucose metabolismShort-term effectsInsulinDiabetes